Multiple myeloma in the very elderly patient: challenges and solutions

References

• AltekruseSFKosaryCLKrapchoMSEER Cancer Statistics Review, 1975–2007Bethesda, MDNational Cancer Institute2010 Available from: http://seer.cancer.gov/csr/1975_2007/index.htmlAccessed February 4, 2016
   Google Scholar
• PalumboABringhenSLudwigHPersonalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Blood2011118174519452921841166
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood200811152516252017975015
   PubMed Web of Science ®Google Scholar
• KumarSKDispenzieriALacyMQContinued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia20132851122112824157580
   PubMed Web of Science ®Google Scholar
• SchaapveldMVisserOSieslingSSchaarCGZweegmanSVellengaEImproved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989Eur J Cancer201046116016919682891
   PubMed Web of Science ®Google Scholar
• FriedLPFerrucciLDarerJWilliamsonJDAndersonGUntangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and careJ Gerontol A Biol Sci Med Sci200459325526315031310
   PubMed Web of Science ®Google Scholar
• WeddingUHoneckerFBokemeyerCPientkaLHöffkenKTolerance to chemotherapy in elderly patients with cancerCancer Control20071414456 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17242670Accessed February 4, 201617242670
   PubMedGoogle Scholar
• HamakerMEJonkerJMde RooijSEVosAGSmorenburgCHvan MunsterBCFrailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic reviewLancet Oncol20121310e437e44423026829
   PubMed Web of Science ®Google Scholar
• HutchinsLFUngerJMCrowleyJJColtmanCAAlbainKSUnder-representation of patients 65 years of age or older in cancer-treatment trialsN Engl J Med1999341272061206710615079
   PubMed Web of Science ®Google Scholar
• KyleRATherneauTMRajkumarSVPrevalence of monoclonal gammopathy of undetermined significanceN Engl J Med2006354131362136916571879
   PubMed Web of Science ®Google Scholar
• TuchmanSAShapiroGRErshlerWBMultiple myeloma in the very old: an IASIA conference reportJ Natl Cancer Inst2014106519
   Google Scholar
• PalumboAAndersonKMultiple MyelomaN Engl J Med20113641046106021410373
   PubMed Web of Science ®Google Scholar
• KyleRAGertzMAWitzigTEReview of 1027 patients with newly diagnosed multiple myelomaMayo Clin Proc200378213312528874
   PubMed Web of Science ®Google Scholar
• HowellDASmithAGJackATime-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research NetworkBMC Hematol2013131924238148
   PubMedGoogle Scholar
• LyratzopoulosGNealRDBarbiereJMRubinGPAbelGAVariation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in EnglandLancet Oncol201213435336522365494
   PubMed Web of Science ®Google Scholar
• GreippPRMiguelJSDuneBGInternational staging system for multiple myelomaJ Clin Oncol200523153412342015809451
   PubMed Web of Science ®Google Scholar
• BirdJMOwenRGD’SaSGuidelines for the diagnosis and management of multiple myeloma 2011Br J Haematol20111541327521569004
   PubMed Web of Science ®Google Scholar
• Avet-LoiseauHHulinCCampionLChromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experienceJ Clin Oncol201331222806280923796999
   PubMed Web of Science ®Google Scholar
• RiccardiAMoraOTinelliCLong-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative group of study and treatment of multiple myelomaBr J Cancer20008271254126010755397
   PubMed Web of Science ®Google Scholar
• KyleRARemsteinEDTherneauTMClinical course and prognosis of smoldering (asymptomatic) multiple myelomaN Engl J Med2007356252582259017582068
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSMateosMGeriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood2015125132068207525628469
   PubMed Web of Science ®Google Scholar
• AntonioPValeriaMSaraBA randomized phase 3 trial of melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) vs lenalidomide plus dexamethsone (Rd) in elderly newly diagnosed multiple myeloma patientsPresented at: ASH Annual Meeting Abstracts 536December 9, 2013Ernest N Morial Convention CenterNew Orleans, LA
   Google Scholar
• LaroccaACavalloFMagarottoVReduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosfamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of ageBlood201312221539539
   Web of Science ®Google Scholar
• BringhenSPetrucciMTLaroccaACarfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studyBlood20141241636924855212
   PubMed Web of Science ®Google Scholar
• KleberMIhorstGGroßBValidation of the Freiburg comorbidity index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcomeClin Lymphoma Myeloma Leuk201313554155123810244
   PubMed Web of Science ®Google Scholar
• BonanadSDe la RubiaJGironellaMDevelopment and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: the GAH scaleJ Geriatr Oncol20156535336126139300
   PubMed Web of Science ®Google Scholar
• ExtermannMAaproMBernabeiRUse of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)Crit Rev Oncol Hematol200555324125216084735
   PubMed Web of Science ®Google Scholar
• PallisAGRingAFortpiedCEortc workshop on clinical trial methodology in older individuals with a diagnosis of solid tumorsAnn Oncol20112281922192621266517
   PubMed Web of Science ®Google Scholar
• MillWBGriffithRThe role of radiation therapy in the management of plasma cell tumorsCancer19804546476526153562
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFEGregoryWMFirst-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialLancet201037697571989199921131037
   PubMed Web of Science ®Google Scholar
• KnudsenLMHippeEHjorthMHolmbergEWestinJRenal function in newly diagnosed multiple myeloma – a demographic study of 1,353 patients. The Nordic Myeloma study groupEur J Haematol19945342072127957804
   PubMed Web of Science ®Google Scholar
• SrkalovicGCameronMGRybickiLDeitcherSRKattke-MarchantKHusseinMAMonoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic diseaseCancer2004101355856615274069
   PubMed Web of Science ®Google Scholar
• PalumboARajkumarSVDimopoulosMAPrevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia200822241442318094721
   PubMed Web of Science ®Google Scholar
• LaroccaACavalloFBringhenSAspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideBlood2012119493393921835953
   PubMed Web of Science ®Google Scholar
• AugustsonBMEarly mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002 – medical research council adult leukaemia working partyJ Clin Oncol200523369219922616275935
   PubMed Web of Science ®Google Scholar
• MarkTMBoyerARossiACClapd (Clarithromycin, Pomalidomide, Dexamethasone) therapy in relapsed or refractory multiple myelomaBlood2013122211955
   Web of Science ®Google Scholar
• BenboubkerLDimopoulosMADispenzieriALenalidomide and dexamethasone in transplant-ineligible patients with myelomaN Engl J Med20143711090691725184863
   PubMed Web of Science ®Google Scholar
• San MiguelJFSchlagRKhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med200828; 3599906917
   Web of Science ®Google Scholar
• PalumboABringhenSLaroccaABortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalJ Clin Oncol201432763464024449241
   PubMed Web of Science ®Google Scholar
• PalumboAHajekRDelforgeMContinuous lenalidomide treatment for newly diagnosed multiple myelomaN Engl J Med2012366191759176922571200
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFEGregoryWMCyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationBlood201111851231123821652683
   PubMed Web of Science ®Google Scholar
• FayersPMPalumboAHulinCThalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trialsBlood201111851239124721670471
   PubMed Web of Science ®Google Scholar
• MiguelJFSchlagRKhuagevaNKPersistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJ Clin Oncol201331444845523233713
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• NiesvizkyRFlinnIWRifkinRCommunity-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimensJ Clin Oncol201533333921392926056177
   PubMed Web of Science ®Google Scholar
• RajkumarSVJacobusSCallanderNSLenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialLancet Oncol2010111293719853510
   PubMed Web of Science ®Google Scholar
• Avet-LoiseauHHulinCBenboubkerLImpact of cytogenetics on outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the first (MM-020) trialBlood201512623730
   Web of Science ®Google Scholar
• DurieBHoeringARajkumarSVBortezomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOGS0777Blood20151262325
   Web of Science ®Google Scholar
• MagarottoVBringhenSMustoPDoublet vs triplet lenalidomide-containing regimens in newly diagnosed myeloma patients, younger or older than 75 years: subgroup analysis of a phase III studyBlood2014124212110
   Web of Science ®Google Scholar
• KastritisEPalumboADimopoulosMATreatment of relapsed/refractory multiple myelomaSemin Hematol200946214315719389498
   PubMed Web of Science ®Google Scholar
• WeberDMChenCNiesvizkyRLenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaN Engl J Med20073572133214218032763
   PubMed Web of Science ®Google Scholar
• JagannathSBarlogieBBerensonJRUpdated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myelomaBr J Haematol2008143453754018783399
   PubMed Web of Science ®Google Scholar
• ArnulfBPylypenkoHGrosickiSUpdated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaHaematologica201297121925192822689676
   PubMed Web of Science ®Google Scholar
• CastelliRPantaleoGGallipoliPSalvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myelomaAnticancer Drugs201526101078108226295869
   PubMed Web of Science ®Google Scholar
• StewartAKRajkumarSVDimopoulosMACarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med2015372214215225482145
   PubMed Web of Science ®Google Scholar
• MoreauPMassziTGrzaskoNIxazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the PhBlood201512623727
   Web of Science ®Google Scholar
• LokhorstHMPlesnerTLaubachJPTargeting CD38 with daratumumab monotherapy in multiple myelomaN Engl J Med2015373131207121926308596
   PubMed Web of Science ®Google Scholar
• LonialSDimopoulosMPalumboAElotuzumab therapy for relapsed or refractory multiple myelomaN Engl J Med2015373762163126035255
   PubMed Web of Science ®Google Scholar
• End of life care for adults [webpage on the Internet]National Institute for Health and Clinical Excellence (NICE) (2011) Available at: https://www.nice.org.uk/guidance/service-delivery-organisation-and-staffing/end-of-life-careAccessed February 25, 2016
   Google Scholar
• San MiguelJFSchlagRKhuagevaNKPersistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJ Clin Oncol201331444845523233713
   PubMed Web of Science ®Google Scholar
• MateosMVOriolAMartínez-LópezJBortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelomLancet Oncol2010111093494120739218
   PubMed Web of Science ®Google Scholar
• RajkumarSVDimopoulosMAPalumboAIMWG updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology20141512e538e54825439696
   PubMed Web of Science ®Google Scholar